Announced Mon, 25 May · 17:54 IST

Press Release titled Fredun Pharmaceuticals Announces 2:1 Bonus Issue, Signaling Strong Growth Confidence

Bonus Above 1to1Corporate Actions View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.3%1-day move
₹2340.00
prior close
₹2379.95
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+2.9+2.9+0.9+2.1-0.3+5.2+1.1+2.8-1.7-1.7+11.8+16.8-60.9
Up moveDown movePending
AI summary

Fredun Pharmaceuticals announced a 2:1 bonus issue of equity shares, where shareholders will receive 2 fully paid-up equity shares of ₹10 each for every 1 existing share held. The Board approved this at its meeting on May 25, 2026, coinciding with the approval of Q4 and FY26 audited financial results. The bonus is subject to shareholder approval and a record date is yet to be announced. For FY26, the company reported total revenues of ₹639.12 crore, EBITDA of ₹94.79 crore, and PAT of ₹33.21 crore. The company highlighted its diversified portfolio spanning generics, nutraceuticals, cosmeceuticals, and pet healthcare as key growth drivers.

Likely market impact

The bonus issue rewards existing shareholders by increasing their shareholding at no cost, signals strong management confidence in future earnings growth, and improves stock liquidity by expanding the number of outstanding shares.